Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics' Q1 Revenues up 75 Percent on Lingering Roche Revenue

NEW YORK (GenomeWeb News) — Epigenomics last week said first-quarter revenue increased 75 percent as R&D spending rose 31 percent and net loss decreased 15 percent.
 
Total receipts for the three months ended March 31, 2007, increased to €820,000 ($1.12 million) from €470,000 ($640,000) year over year.
 
Epigenomics said the revenue in part came from a collaboration with Roche Diagnostics, which officially ended on March 14, from several ongoing biomarker collaborations, and from a partnership with Centocor.
 
R&D spending increased to €2.5 million from €1.9 million year over year.
 
The company said its net loss was €3.4 million, compared with €4 million in the year-ago period.
 
Epigenomics said it had around €13.7 million in liquid assets as of March 31.
 
CEO Geert Nygaard said in a statement that Epigenomics’ blood-based colorectal cancer screening test and an improved assay procedure for detecting cancers will be the key drivers for future revenues, and that developing those programs will be the company’s main priority in 2007.
 
The company said it expects revenue of around €3.6 million for full year 2007.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.